Your testosterone is normal but you feel feminized. Your genes may be converting too much.

Your androgen receptor is the lock that testosterone fits into. It sits on the surface of muscle cells, prostate cells, bone cells, and brain cells. When testosterone binds to it, it triggers a cascade of gene expression: muscle growth, sexual motivation, confidence, and aggressive metabolic rate. The strength of this response depends entirely on your androgen receptor structure.

The AR gene contains a CAG repeat segment. The number of times this sequence repeats determines how sensitive your cells are to testosterone. Short repeats (16-25 repeats) make your receptor highly sensitive; long repeats (26+ repeats) make it less sensitive. Roughly 20-30% of men carry longer CAG repeats that reduce androgen receptor sensitivity. You can have plenty of testosterone in your bloodstream, but if your androgen receptor doesn’t respond efficiently, your body acts as though you’re testosterone-deficient.

This translates to low libido despite normal or high testosterone levels. Difficulty building muscle despite heavy training. Reduced bone density. Emotional sensitivity and mood changes. Your brain doesn’t feel as driven; your muscles don’t respond as aggressively to training; your metabolism doesn’t run as hot. Meanwhile, your aromatase enzyme is still converting testosterone into estrogen at normal rates, so estrogen’s effects (fluid retention, breast sensitivity, reduced motivation) become relatively dominant.

SHBG is a transport protein made by your liver. Its job is to bind testosterone and estrogen in your bloodstream, inactivating them. Only unbound (free) hormone can actually enter cells and trigger biological effects. Think of SHBG as a catcher’s mitt that holds the hormone until it’s needed. The more SHBG you produce, the less free testosterone and estrogen you have available.

The SHBG gene has common variants (rs6259, rs1799941) that influence how much SHBG your liver produces. Roughly 30-40% of men carry variants associated with higher SHBG production. Higher SHBG sounds like it should reduce estrogen, but the problem is it reduces free testosterone even more, making the testosterone-to-estrogen ratio worse. Your total estrogen may not be dramatically elevated, but your free testosterone is suppressed, and your free estrogen ratio becomes unfavorable.

You experience this as low libido, reduced muscle-building capacity despite adequate total testosterone, and a feeling that hormone replacement therapy doesn’t work well because the SHBG is still binding it all up. Your energy feels flat; your sexual motivation is muted; your metabolism doesn’t run as fast as it should.

Aromatase is the enzyme that catalyzes the conversion of testosterone into estrogen. It’s essential for bone health, cardiovascular function, and brain development; every man needs some baseline estrogen. But when aromatase activity is too high, relative to your ability to clear estrogen, testosterone gets shunted away from muscle-building and sexual function and gets converted into estrogen instead.

The CYP19A1 gene has several common variants that increase aromatase expression and activity. Roughly 25-35% of men carry variants associated with higher aromatase activity. Higher aromatase means your body converts a larger percentage of testosterone into estrogen, pushing you toward an unfavorable hormone ratio. This is especially pronounced if you carry certain MTHFR or COMT variants that also impair estrogen clearance.

You feel this as low libido, difficulty building muscle despite adequate testosterone levels, fat storage around the abdomen and chest (estrogen-dependent fat distribution), and potential breast tissue sensitivity or growth. Your sexual motivation is low; your body composition is stubborn; your strength gains plateau despite consistent training.

COMT has two primary jobs relevant to hormone balance. First, it clears dopamine and norepinephrine from your brain and tissues. Second, it’s involved in estrogen metabolism; specifically, it methylates estrogen metabolites to make them easier to excrete. The Val158Met variant is the most common COMT polymorphism. The Met allele (slow variant) is carried by roughly 25% of men homozygously and another 50% heterozygously.

If you carry the slow COMT variant, you clear dopamine slowly (leaving you with higher baseline dopamine but reduced dopamine responsiveness to stimulation) and you metabolize estrogen metabolites slowly. Slow estrogen clearance combined with high aromatase means estrogen accumulates in your tissues because you can’t convert it to excretable forms fast enough. This is compounded if you also have MTHFR variants that reduce methylation capacity generally.

You experience this as low sexual motivation (estrogen suppresses dopamine-dependent sexual drive), emotional blunting, reduced competitive drive, fatigue despite adequate sleep, and an inability to mobilize energy under stress. Your arousal response is sluggish; your motivation is dampened; your muscles feel flat despite training.

The VDR (vitamin D receptor) is a nuclear receptor that activates vitamin D’s biological effects. Vitamin D, despite its name, is actually a hormone precursor. It travels to your VDR, binds it, and triggers expression of hundreds of genes involved in immune function, bone metabolism, and hormone regulation, including testosterone synthesis and estrogen metabolism.

The VDR gene has four common polymorphisms (FokI, BsmI, ApaI, TaqI) that affect how efficiently your body responds to vitamin D. The FokI variant, in particular, exists in two lengths; the shorter form (ff) is more transcriptionally active. Roughly 35-45% of men carry the longer form (FF or Ff), which reduces vitamin D receptor sensitivity. Poor VDR function means your tissues can’t respond adequately to vitamin D, even if your serum 25(OH)D levels are normal. This impairs testosterone synthesis and estrogen metabolism.

You experience this as low testosterone despite adequate sun exposure or supplementation, poor estrogen clearance despite supplementing with DIM or other estrogen-support tools, weak immune response, low mood, and difficulty maintaining bone density. Your sexual motivation is low; your mood is flat; supplements that should work don’t seem to have much effect.

MTHFR is the rate-limiting enzyme in the folate cycle, the metabolic pathway that produces methyl groups used throughout your body. Methyl groups are used in DNA synthesis, neurotransmitter production, and crucially, the detoxification and excretion of estrogen. MTHFR converts folate into its active form (methylfolate), which feeds into the methylation cycle. If MTHFR is impaired, your methylation capacity suffers globally.

The MTHFR C677T variant reduces enzyme efficiency by 35-70%, depending on whether you’re heterozygous or homozygous. Roughly 40% of people of European ancestry carry at least one copy of this variant. Reduced methylation capacity means your body cannot efficiently convert estrogen into its excretable forms and cannot efficiently clear estrogen metabolites from your system. Estrogen accumulates. This is compounded if you also have slow COMT.

You experience this as elevated estrogen despite normal or even low total testosterone, persistent low libido, difficulty losing weight (estrogen promotes fat storage), brain fog, poor mood stability, and an inability to respond to standard estrogen-support supplements. Your sexual function is persistently low; your energy is inconsistent; your mood is reactive.